Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients

Acta Haematologica

Volumn 116, Issue 4, 2006, Pages 229-237

  Specchia, Giorgina ^a   Pastore, Domenico ^a   Mestice, Anna ^a   Liso, Arcangelo ^a   Carluccio, Paola ^a   Leo, Manuela ^a   Casanova, Margherita ^a   Sibilla, Silvia ^a   Giannoccaro, Margherita ^a   Liso, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Engraftment, early and long term; Myeloid leukemia, acute; Peripheral stem cell transplantation; Subset CD34

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; THY 1 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CD34 SELECTION; CELL SUBPOPULATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CRYOPRESERVATION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; NEUTROPHIL; NEUTROPHIL COUNT; PRIORITY JOURNAL; SURVIVAL TIME; THAWING; THROMBOCYTE COUNT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD34; BLOOD CELL COUNT; BLOOD PLATELETS; FEMALE; GRAFT SURVIVAL; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33751276844     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095872     Document Type: Article

References (32)

1. Gratwohl A, Passweg J, Baldomero H, Hermans J: Blood marrow transplantation activity in Europe 1997. European Group for Blood Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;24:231-245.
2. Korbling M, Fliedner TM, Holle R, Magrin S, Baumann M, Holdermann E, Eberhardt K: Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the auto graft on hematopoietic reconstitution and disease free survival. Bone Marrow Transplant 1991;7:343-349.
3. De La Rubia J, Sanz JF, Martin G, Martinez J, Cervera J, Solves P, Jimenez C, Arnao M, Vicente A, Jarque I, Sempere A, Sanz MA: Autologous blood stem cell transplantation for acute myeloid leukemia in first complete remission: intensification before transplantation does not prolong disease-free survival. Haematologica 1999;48:125-132.
4. To LB, Robert MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQ, Dart GW, Horvath N, Davy ML: Comparison of the haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplant, autologous bona marrow transplant and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-284.
5. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Stieger W: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral blood stem cell or bone marrow: A randomized comparison. J Clin Oncol 1995;13:1328-1335.
6. Brendel C, Neubauer A: Characteristics and analysis of normal and leukemic stem cells: current concepts and future direction. Leukemia 2000;14:1711-1717.
7. Craig W, Kay R, Cutler RL, Landsorp M: Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177:1331-1342.
8. Humeau L, Bardin F, Maroc C, Alario T, Galindo R, Mannoni P, Chabannon C: Phenotypic, molecular and functional characterization of human peripheral blood CD34+/Thy-1+ cells. Blood 1996;87:4109-4119.
9. Henon P, Solovat H, Bourderont D, Ojeda-Uribe M, Arkan Y, Raidot JP, Husseini F, Audhuy B: Role of CD34+CD38- cells in post-transplant hematopoietic recovery. Stem Cells 1998;16(suppl 1):113-122.
10. Shimazaki C, Sumikuma T, Inaba T: CD34+CD90+ cell and late hematopoietic reconstitution after autologous peripheral blood stem cell transplantation. Leuk Lymphoma 2004;45:661-668.
11. Sumikuma T, Shimazaki C, Inaba T, Ochiai N, Okano A, Hatsuse M, Ashihara E, Nakagawa M: CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002;117:238-244.
12. Millar BC, Millar JL, Shepard V, Blackwell P, Porter H, Cunningham D, Judson I, Treleaven J, Powles RL, Catovsky D: Importance of CD34+/CD33- cells in platelets engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998;22:469-475.
13. Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S, Doria L, Isaacs R, Gillio AP, Michelis MA, Brochstein JA: CD34+CD33-cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 1998;16:2093-2104.
14. Mayol AS, Vital JB, Llodra AG, Flori NM, Sureda MM, Garcia AN, Riera MM, Bach EG, Garcia PM: CD34+ cell dose and CD33- subset: collection and engraftment kinetics in autologous peripheral blood stem cell transplantation. Haematologica 1998;83:489-495.
15. Knudsen LM, Jensen L, Jarbaek L, Hansen PG, Hansen SW, Drivsholm L, Nikolaisen K, Gaarsdal E, Johnsen HE: Subset of CD34+ hematopoietic progenitor and platelet recovery after high dose chemotherapy and peripheral stem cell transplantation. Haematologica 1999;84:517-524.
16. Duggan PR, Guo D, Luider J, Auer I, Klassen J, Chaudhry A, Morris D, Gluck S, Brown CB, Russell JA, Stewart DA: Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant 2000;26:1299-1304.
17. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Ching E, Morris D, Chaudhry A, Brown C, Russell JA: Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant 1999;23:1237-1243.
18. Stewart DA, Guo D, Luider J, Auer I, Morris D, Chaudhry A, Brown C, Russell JA, Gluck S: The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well the total CD34+ cell dose. Bone Marrow Transplant 2000;25:435-440.
19. Pastore D, Specchia G, Mestice A, Liso A, Pannunzio A, Carluccio P, Buquicchio C, Greco G, Ciuffreda L, Pietrantuono G, Liso V: Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant 2004;33:1083-1087.
20. Ojeda-Uribe M, Sovalat H, Bourderont D, Brunot A, Marr A, Lewandowski H, Chaboute V, Peter P, Henon P: Peripheral blood BM CD34+ CD38- cells show better resistance to cryopreservation than CD34+ CD38+ cells in autologous stem cell transplantation. Cytotherapy 2004;6.571-583.
21. Sartor M, Antoneas V, Garvin F, Webb M and Bradstock KF: Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 2005;36:199-204.
22. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH: Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29.967-972.
23. Keeney M, Brown W, Gratama J, Papa S, Lanza F, Sutherland DR: Immunophenotypic characterization of CD34(pos) cells. J Biol Regul Homeost Agents 2003;17:254-260.
24. Worel R, Greinix H, Keil F, Mitterbauer M, Lechner K, Fischer G, Mayr W, Hocher P, Kalhs P: Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after non-myeloablative than myeloablative conditioning. Transfusion 2004;42:1293-1301.
25. Pratt G, Rawstron AC, English RJ, Jack AS, Morgan GJ, Smith GM: Analysis of CD34+ cell subsets in stem cell harvest can more reliably predict rapidity and durability of engraftment than the total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001;114:937-943.
26. Bolwell B, Goormastics M, Anderson S, Koo A, Wise K, Overmoyer B, Pohlman B, Kalaycio M: Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998;22:547-551.
27. Perey L, Peters R, Pampallona S, Schneider P, Gross N, Leyvraz S: Extensive phenotypic analysis of CD34 subsets in successive collections of mobilized peripheral blood progenitors. Br J Haematol 1998;103:618-629.
28. Michallet M, Philip T, Philip I, Godinot H, Sebban C, Salles G, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fiere D, Archimbaud E: Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol 2000;28:858-870.
29. Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizurn JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J: Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000;6:262-271.
30. Drake M, Ranaghan EA, Alexander HD, Desai ZR, Morris TC: CD34+CD38-HLA-DR- correlate more closely than CD34+CD38- with engraftment post-PBSC transplantation. Br J Haematol 1999;104:643-644.
31. Melillo L, Specchia G, Ferrara F, Minervini MM, Pastore D, Carella AM: Evaluation of leukemic contamination in peripheral blood stem cell leukaphereses vs. bone marrow after consolidation therapy in acute myeloid leukemia: not a critical factor in outcome? Haematologica 2003;88:715-718.
32. Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R, EORTC Leukemia Group, GIMEMA Leukemia Group: The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: Results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003;17:60-67.